Covered recipient · General Payments record
ARUN CHANDRAKANTAN
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$2,967.32
- Reported across 79 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $422.05 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $247.40 | 9 |
| Eurofins Viracor, Inc. | $68.33 | 2 |
| OPKO Pharmaceuticals, LLC | $21.49 | 1 |
| Fresenius USA Marketing, Inc. | $20.55 | 1 |
| Merck Sharp & Dohme Corporation | $19.31 | 1 |
| Acerta Pharma LLC | $14.99 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $14.99 | 1 |
| Alexion Pharmaceuticals, Inc. | $14.99 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $14.99 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093891668 | CMS |
| Amgen Inc. | $29.54 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545683 | CMS |
| Amgen Inc. | $31.13 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545685 | CMS |
| Amgen Inc. | $32.02 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545687 | CMS |
| Amgen Inc. | $26.84 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545689 | CMS |
| Amgen Inc. | $30.68 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545691 | CMS |
| Amgen Inc. | $25.89 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545693 | CMS |
| Amgen Inc. | $29.13 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545695 | CMS |
| Amgen Inc. | $19.10 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545697 | CMS |
| Amgen Inc. | $23.07 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545699 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.99 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104692152 | CMS |
| Eurofins Viracor, LLC | $52.50 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141911802 | CMS |
| Eurofins Viracor, LLC | $15.83 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146421789 | CMS |
| Fresenius USA Marketing, Inc. | $20.55 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154206716 | CMS |
| Merck Sharp & Dohme LLC | $19.31 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141862619 | CMS |
| Novartis Pharmaceuticals Corporation | $14.99 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086782221 | CMS |
| OPKO Pharmaceuticals, LLC | $21.49 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112843326 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.